Get the Daily Brief
Latest Biotech News
Regeneron Rolls Out Proteomics Study on 200K Geisinger Samples with Olink Platform
Regeneron Genetics Center has launched a large-scale proteomics research initiative involving nearly 200,000 patient samples from Geisinger, using Thermo Fisher's Olink Explore HT platform. This...
Brain Implant Lets Man with ALS Speak and Sing with His ‘Real Voice’
A novel brain-computer interface featuring 256 implanted electrodes successfully enabled a man with severe speech paralysis from ALS to communicate expressively and modulate his voice in real...
Capricor Receives FDA Form 483 with Observations at Manufacturing Site
Capricor Therapeutics has been issued a Form 483 following an FDA inspection of its manufacturing facility, citing several observations primarily related to quality systems and documentation....
Regeneron Launches Massive Proteomics Initiative with Thermo Fisher
Regeneron Genetics Center (RGC) has initiated an extensive proteomics research project analyzing nearly 200,000 Geisinger Health System patient samples using Thermo Fisher Scientific’s Olink...
AI Accelerates Alzheimer’s Gene Research at Tempus and Northwestern
Tempus AI and Northwestern University's Abrams Research Center are collaborating to apply AI-driven data analytics to genomic data focused on Alzheimer's disease. Using Tempus’ Lens platform, the...
BioNTech Acquires CureVac to Boost mRNA Cancer Development
BioNTech has agreed to acquire CureVac in an all-stock deal valued around $1.25 billion, marking a strategic expansion of its mRNA platforms for cancer immunotherapy. The acquisition focuses...
SpliceBio Closes $135 Million Series B for Stargardt Gene Therapy
SpliceBio has secured $135 million in Series B financing to complete clinical development of SB-007, a dual AAV vector gene therapy for Stargardt’s disease, a leading inherited retinal disorder...
MaxCyte and Ori Biotech Partner to Optimize Cell Therapy Manufacturing
MaxCyte and Ori Biotech have entered a strategic collaboration to enhance manufacturing efficiency and scalability for autologous cellular therapies. The partnership combines MaxCyte’s...
Novel Brain-Computer Interface Enables ALS Patient to Speak and Sing
Researchers have developed an instantaneous brain-to-voice neuroprosthesis allowing a man with amyotrophic lateral sclerosis (ALS) to communicate using synthesized speech reproducing his own...
Synthetic Biology Boosts Monoclonal Antibody Production by Taming Cellular Evolution
Enduro Genetics reports a pioneering synthetic biology approach that counters cellular micro-evolution during monoclonal antibody (mAb) manufacturing. By harnessing biosensors and regulatory...
Bristol Myers Squibb Gains $350M Radiopharmaceutical Asset for Prostate Cancer
Bristol Myers Squibb’s RayzeBio unit licensed exclusive global rights to Philochem's OncoACP3, a prostate cancer-targeting diagnostic and radiopharmaceutical therapeutic candidate, via a $350...
Eli Lilly Invests Over $650M in Juvena for Muscle-Enhancing Therapies
Eli Lilly has partnered with Juvena Therapeutics in a deal featuring upfront payments and milestones exceeding $650 million to develop muscle health drugs. Juvena’s AI-driven platform maps...
Merck’s Cesrovimab Approved for Pediatric RSV Amid CDC Advisory Uncertainty
Merck received FDA approval for Enflonsia (cesrovimab), a long-acting monoclonal antibody to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in newborns and...
BioNTech to Acquire CureVac in $1.25 Billion Stock Deal
BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating their positions in mRNA-based cancer immunotherapies and vaccines. This strategic move aims to...
SpliceBio Raises $135M Series B for Stargardt Gene Therapy
SpliceBio secured $135 million to advance its dual AAV gene therapy targeting Stargardt disease, a significant step for treating inherited retinal disorders. The financing bolsters clinical...
Genentech Layoffs Hit 143 Employees Amid Strategic Restructuring
Genentech announced workforce reductions of 143 roles at its South San Francisco headquarters as part of efforts to streamline operations. The layoffs follow prior cuts and organizational changes,...
BioNTech and CureVac Merger Boosts mRNA Cancer Therapy
BioNTech announced plans to acquire CureVac for $1.25 billion in an all-stock deal, consolidating two mRNA-focused biotechs. This acquisition enhances BioNTech's pipeline in cancer immunotherapy...
FDA Grants Sarepta Platform Technology Designation
The FDA has conferred a platform technology designation to Sarepta Therapeutics, aiming to streamline regulatory reviews for gene therapies the company may develop. This status is part of FDA...
Schrödinger Presents Early Phase 1 Data on MALT1 Inhibitor
Schrödinger reported preliminary safety and efficacy signals from an ongoing Phase 1 trial evaluating its MALT1 inhibitor. The findings reinforce the utility of the company's computational drug...
Nuvation Bio Secures FDA Approval for Lung Cancer Drug
Nuvation Bio received FDA approval for Ibtrozi (taletrectinib), targeting advanced ROS1-positive non-small cell lung cancer. Approval was based on robust response rates reported in multiple...